These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 26292923

  • 1. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
    Thiagamoorthy G, Giarenis I, Cardozo L.
    Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D, Thiagamoorthy G, Cardozo L.
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M, Nukui A, Kamai T.
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [Abstract] [Full Text] [Related]

  • 11. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
    Giarenis I, Robinson D, Cardozo L.
    Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
    [Abstract] [Full Text] [Related]

  • 12. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR, Siddiqui E.
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
    Andersson KE, Martin N, Nitti V.
    J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview.
    Kaya E, Sikka SC, Oral DY, Ozakca I, Gur S.
    Curr Drug Targets; 2018 Oct; 19(6):602-612. PubMed ID: 28117002
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.